NASDAQ:VXRT Vaxart (VXRT) Stock Price, News & Analysis $0.46 0.00 (-0.56%) Closing price 05/27/2025 04:00 PM EasternExtended Trading$0.47 +0.01 (+1.32%) As of 05/27/2025 07:54 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Vaxart Stock (NASDAQ:VXRT) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Vaxart alerts:Sign Up Key Stats Today's Range$0.46▼$0.4850-Day Range$0.31▼$0.5252-Week Range$0.29▼$1.07Volume1.23 million shsAverage Volume2.43 million shsMarket Capitalization$105.19 millionP/E RatioN/ADividend YieldN/APrice Target$3.00Consensus RatingBuy Company OverviewVaxart, Inc., a clinical-stage biotechnology company, discovers and develops oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company's product pipeline includes norovirus vaccine, a bivalent oral tablet vaccine in Phase 2 clinical trial for the GI.1 and GII.4 norovirus strains; coronavirus vaccine, which is in Phase 2 clinical trial, for the treatment of SARS-CoV-2 infection; seasonal influenza vaccine, which is in Phase 2 clinical trial, to treat H1 influenza infection; and human papillomavirus therapeutic vaccine, which is in preclinical stage, that targets HPV-16 and HPV-18 for cervical cancers and precancerous cervical lesions. It has a license agreement with Altesa Biosciences, Inc. to develop and commercialize Vapendavir, a capsid-binding broad-spectrum antiviral. Vaxart, Inc. is headquartered in South San Francisco, California.Read More… Vaxart Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks53rd Percentile Overall ScoreVXRT MarketRank™: Vaxart scored higher than 53% of companies evaluated by MarketBeat, and ranked 510th out of 920 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingVaxart has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageVaxart has only been the subject of 1 research reports in the past 90 days.Read more about Vaxart's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Vaxart are expected to grow in the coming year, from ($0.39) to ($0.38) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Vaxart is -1.12, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Vaxart is -1.12, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioVaxart has a P/B Ratio of 1.21. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Vaxart's valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted5.28% of the outstanding shares of Vaxart have been sold short.Short Interest Ratio / Days to CoverVaxart has a short interest ratio ("days to cover") of 6.4.Change versus previous monthShort interest in Vaxart has recently decreased by 8.43%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldVaxart does not currently pay a dividend.Dividend GrowthVaxart does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted5.28% of the outstanding shares of Vaxart have been sold short.Short Interest Ratio / Days to CoverVaxart has a short interest ratio ("days to cover") of 6.4.Change versus previous monthShort interest in Vaxart has recently decreased by 8.43%, indicating that investor sentiment is improving significantly. News and Social Media3.2 / 5News Sentiment0.80 News SentimentVaxart has a news sentiment score of 0.80. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 1.03 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 5 news articles for Vaxart this week, compared to 1 article on an average week.Search Interest7 people have searched for VXRT on MarketBeat in the last 30 days. This is an increase of 17% compared to the previous 30 days.MarketBeat Follows7 people have added Vaxart to their MarketBeat watchlist in the last 30 days. This is an increase of 17% compared to the previous 30 days. Company Ownership1.7 / 5Insider TradingAcquiring Shares Insider Buying vs. Insider SellingIn the past three months, Vaxart insiders have bought more of their company's stock than they have sold. Specifically, they have bought $49,000.00 in company stock and sold $0.00 in company stock.Percentage Held by InsidersOnly 2.90% of the stock of Vaxart is held by insiders.Percentage Held by InstitutionsOnly 18.05% of the stock of Vaxart is held by institutions.Read more about Vaxart's insider trading history. Receive VXRT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Vaxart and its competitors with MarketBeat's FREE daily newsletter. Email Address VXRT Stock News HeadlinesVaxart, Inc. (NASDAQ:VXRT) Insider Steven Lo Acquires 100,000 SharesMay 20, 2025 | insidertrades.comVaxart (NASDAQ:VXRT) vs. Brainstorm Cell Therapeutics (NASDAQ:BCLI) Head to Head ContrastMay 28 at 2:07 AM | americanbankingnews.comMan who predicted $100K Bitcoin sees a huge run coming for another coin …Sure enough, Bitcoin took off on the exact day Juan said it would. It's up more than 40% since the election … surpassing $100,000 on Dec. 8 .… Now Juan believes it could hit $150,000 … or higher in 2025.May 28, 2025 | Weiss Ratings (Ad)Vaxart Initiates Dosing in 10,000-Participant Portion of Phase 2b COVID-19 TrialMay 27 at 8:00 AM | globenewswire.comVaxart (NASDAQ:VXRT) Raised to Hold at Wall Street ZenMay 25 at 3:39 AM | americanbankingnews.comVaxart Announces Adjournment of Annual Meeting of StockholdersMay 21, 2025 | globenewswire.comVaxart, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | VXRT Stock NewsMay 20, 2025 | gurufocus.comVaxart, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)May 20, 2025 | globenewswire.comSee More Headlines VXRT Stock Analysis - Frequently Asked Questions How have VXRT shares performed this year? Vaxart's stock was trading at $0.6621 at the beginning of the year. Since then, VXRT shares have decreased by 30.4% and is now trading at $0.4609. View the best growth stocks for 2025 here. How were Vaxart's earnings last quarter? Vaxart, Inc. (NASDAQ:VXRT) released its earnings results on Tuesday, May, 13th. The biotechnology company reported ($0.07) EPS for the quarter, hitting the consensus estimate of ($0.07). The biotechnology company had revenue of $20.88 million for the quarter, compared to analyst estimates of $2.85 million. Vaxart had a negative trailing twelve-month return on equity of 110.46% and a negative net margin of 431.61%. Read the conference call transcript. When did Vaxart's stock split? Shares of Vaxart reverse split on Wednesday, February 14th 2018. The 1-11 reverse split was announced on Tuesday, February 13th 2018. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, February 13th 2018. An investor that had 100 shares of stock prior to the reverse split would have 9 shares after the split. Who are Vaxart's major shareholders? Vaxart's top institutional investors include Jones Financial Companies Lllp (0.21%), Invesco Ltd. (0.06%), Virtu Financial LLC (0.06%) and Goldman Sachs Group Inc. (0.03%). Insiders that own company stock include W Mark Watson and Fuad Ahmad. View institutional ownership trends. How do I buy shares of Vaxart? Shares of VXRT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Vaxart own? Based on aggregate information from My MarketBeat watchlists, some other companies that Vaxart investors own include Plug Power (PLUG), Workhorse Group (WKHS), FuelCell Energy (FCEL), Fortress Biotech (FBIO), Assertio (ASRT), Ovid Therapeutics (OVID) and KALA BIO (KALA). Company Calendar Last Earnings5/13/2025Today5/27/2025Next Earnings (Estimated)8/14/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:VXRT Previous SymbolNASDAQ:NABI CIK72444 Webwww.vaxart.com Phone(650) 550-3500Fax650-871-8580Employees120Year Founded2004Price Target and Rating Average Stock Price Target$3.00 High Stock Price Target$4.00 Low Stock Price Target$2.00 Potential Upside/Downside+552.2%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($0.27) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-82,460,000.00 Net Margins-431.61% Pretax Margin-430.07% Return on Equity-110.46% Return on Assets-62.78% Debt Debt-to-Equity RatioN/A Current Ratio0.83 Quick Ratio0.83 Sales & Book Value Annual Sales$47.40 million Price / Sales2.22 Cash FlowN/A Price / Cash FlowN/A Book Value$0.38 per share Price / Book1.21Miscellaneous Outstanding Shares228,223,000Free Float221,566,000Market Cap$104.98 million OptionableOptionable Beta1.27 Social Links Free Today: Your Guide to Smarter Options TradesLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free Report This page (NASDAQ:VXRT) was last updated on 5/28/2025 by MarketBeat.com Staff From Our PartnersTrump Predicts Dollar DownfallREAD THIS VERY CAREFULLY: If you have $100,000 or more saved for retirement, this may make you VERY angry... ...Augusta Precious Metals | SponsoredJuly 2025 Rule Change to Impact Retirement InvestorsThere's a massive change from a new rule going into effect this July. And it's one the Big Banks are alread...Premier Gold Co | SponsoredAI Meltdown Imminent: Dump These Stocks Now!If you have any money in the markets, especially in AI stocks… Please click here to see Elon Musk’s new inv...Paradigm Press | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredF1 Engineering Powers This Electric Marine MotorThe future of marine propulsion has arrived - powered by F-1 grade engineering. In collaboration with McLar...The Tomorrow Investor | SponsoredBanks aren’t ready for this altcoin—are you?While everyone's distracted by Bitcoin's moves, a stealth revolution is underway. One altcoin is quietly po...Crypto 101 Media | SponsoredNow I look stupid. Real stupid... I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredThink NVDA’s run was epic? You ain’t seen nothin’ yetAsk most investors and they’ll probably tell you Nvidia is the undisputed AI stock of the decade. In 2023, ...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Vaxart, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Vaxart With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.